Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Mochida Pharmaceutical Co., Ltd. ( (JP:4534) ) has issued an announcement.
Mochida Pharmaceutical reported solid growth for the fiscal year ended March 31, 2026, with net sales rising 11.2% to ¥116.95 billion and profit attributable to owners of parent climbing 39.0% to ¥7.90 billion, reflecting improved margins and stronger ordinary profit. Despite a decline in cash and cash equivalents due to negative operating and investing cash flows, total assets and net assets increased, while the company maintained an annual dividend of ¥80 per share and guided for further growth in fiscal 2027, projecting a 7.7% rise in sales and a 26.5% jump in profit with a planned dividend hike to ¥85 per share.
The company’s profitability indicators improved, with return on equity rising to 5.8% and the ratio of operating profit to net sales reaching 8.7%, supported partly by a swing to positive equity-method earnings. Although the equity-to-asset ratio eased to 76.8% from 81.6% as assets expanded, management signaled confidence via higher earnings forecasts, indicating a continued commitment to shareholder returns through stable and gradually increasing dividends.
More about Mochida Pharmaceutical Co., Ltd.
Mochida Pharmaceutical Co., Ltd. is a Japan-based drug maker listed on the Tokyo Stock Exchange, operating under Japanese GAAP. The company develops, manufactures, and sells pharmaceutical products, with its earnings driven primarily by prescription drugs, and focuses on improving profitability and shareholder returns through stable dividends.
Average Trading Volume: 109,694
Technical Sentiment Signal: Buy
Current Market Cap: Yen115.5B
See more insights into 4534 stock on TipRanks’ Stock Analysis page.